NextCell Pharma publishes prospectus supplement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a supplement to the prospectus regarding the invitation to subscribe for shares in the Company’s resolved rights issue, which was approved by the Swedish Financial Supervisory Authority on 3 December 2020, and published on the same day. The prospectus supplement has been prepared due to the information in the Company’s press release om 10 December 2020 regarding results in the Company’s continuation study ProTrans-Repeat and the Company’s press release on 15 December 2020 regarding the observation study ProTrans-OBS.
The supplement, which today on 16 December 2020 has been approved and registered by the Swedish Financial Supervisory Authority, forms part of and must be read together with, the prospectus. The supplement and the prospectus are available on the Company’s website, www.nextcellpharma.com.
Investors who before the publication of the supplement have applied for, or in any other manner consented to, subscription of shares in the rights issue have, under Article 23 of Regulation (EU) 2017/1129 of the European Parliament and of the Council, the right to withdraw their application or consent within two working days from the publication of the supplementary prospectus, i.e., up to and including 18 December 2020. A withdrawal shall be made in writing to Avanza Bank AB, Box 111 93 Stockholm or via e-mail to corpemissioner@avanza.se. Applications that are not withdrawn within the prescribed time will remain binding. No measure is required for investors wishing to withhold their subscription of shares.
Advisors
Vator Securities AB is financial advisor, and Eversheds Sutherland Advokatbyrå AB is legal advisor to NextCell in connection with the rights issue. Avanza Bank AB is issuing agent in connection with the rights issue.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.